Compare Amphastar Pharmaceuticals Inc (AMPH) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Noble Corporation plc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Noble Corporation plc trades at $40.05 (market cap $6.38B). The key difference: Noble Corporation plc is far larger — about 7.7× Amphastar Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 5% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NE | |
|---|---|---|
Market Cap | $826.08M | $6.38B |
Sector | Health | Technology |
52-Week High | $30.81 | $54.37 |
52-Week Low | $16.87 | $25.70 |
Enterprise Value | $1.22B | $7.63B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Noble Corporation (NE) trades at $39.97, up 2.75% today, with a bearish technical signal and mixed quarterly earnings. The company maintains solid cash flow, with $228M net cash flow in 2025, and recently secured a three-well UKCS contract from BP. Valuation metrics show a P/E of 27.95 and EV/EBITDA of 7.2, while analyst consensus is divided with a $50 price target.
Outlook is cautious due to recent earnings misses and bearish technicals, but strong operational cash flow and new contracts offer stability. Risks include execution challenges and oil market volatility, while the dividend and low leverage provide shareholder support. Investors should weigh fundamental strength against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
